Was 4-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?

被引：14
|
作者：
Neuhoff, Sibylle [1 ]
Tucker, Geoffrey T. [2 ]
机构：
[1] Simcyp Certara Ltd, Sheffield, S Yorkshire, England
[2] Univ Sheffield, Sheffield, S Yorkshire, England
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2018年 / 84卷 / 07期
关键词：
4-hydroxycholesterol; biomarker; CYP3A4; CONCISE GUIDE; 4-BETA-HYDROXYCHOLESTEROL; METABOLISM; RIFAMPICIN;
D O I：
10.1111/bcp.13538
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1620 / 1621
页数：2
相关论文
共 50 条
  • [1] Kuypers and Vanhove reply to "Was 4-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker
    Kuypers, Dirk R. J.
    Vanhove, Thomas
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (07) : 1622 - 1623
  • [2] Gjestad et al. reply to "Was 4-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker
    Gjestad, Caroline
    Haslemo, Tore
    Andreassen, Ole A.
    Molden, Espen
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (07) : 1624 - 1625
  • [3] 4β-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans
    Diczfalusy, Ulf
    Nylen, Hanna
    Elander, Pontus
    Bertilsson, Leif
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (02) : 183 - 189
  • [4] A comparison of 4-hydroxycholesterol:cholesterol and 6-hydroxycortisol:cortisol as markers of CYP3A4 induction
    Arrhen, Yvonne Marde
    Nylen, Hanna
    Lovgren-Sandblom, Anita
    Kanebratt, Kajsa P.
    Wide, Katarina
    Diczfalusy, Ulf
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (06) : 1536 - 1540
  • [5] 4-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes
    de Graan, Anne-Joy M.
    Sparreboom, Alex
    de Bruijn, Peter
    de Jonge, Evert
    van der Holt, Bronno
    Wiemer, Erik A. C.
    Verweij, Jaap
    Mathijssen, Ron H. J.
    van Schaik, Ron H. N.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (03) : 560 - 568
  • [6] 4β-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man
    Luetjohann, D.
    Marinova, M.
    Schneider, B.
    Oldenburg, J.
    von Bergmann, K.
    Bieber, T.
    Bjorkhem, I.
    Diczfalusy, U.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2009, 47 (12) : 709 - 715
  • [7] CYP3A4 phenotyping by plasma 4β-hydroxycholesterol?
    Fuhr, U.
    Doroshyenko, O.
    Frank, D.
    Tomalik-Scharte, D.
    Jetter, A.
    Luetjohann, D.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2007, 101 (05) : 372 - 372
  • [8] 4-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients
    Gjestad, Caroline
    Haslemo, Tore
    Andreassen, Ole A.
    Molden, Espen
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (11) : 2398 - 2405
  • [9] Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice
    Nitta S.-I.
    Hashimoto M.
    Kazuki Y.
    Takehara S.
    Suzuki H.
    Oshimura M.
    Akita H.
    Chiba K.
    Kobayashi K.
    The AAPS Journal, 20 (3)
  • [10] Genetic and clinical determinants of CYP3A4 activity in patients using 4β-hydroxycholesterol as an in vivo probe
    Gong, Inna Ying
    DeGorter, Marianne K.
    Schwarz, Ute I.
    Yin, Peter
    Choi, Yun Hee
    Tirona, Rommel G.
    Kim, Richard B.
    FASEB JOURNAL, 2013, 27
12345